Drug Profile
Formoterol/fluticasone propionate - Mundipharma International/Vectura
Alternative Names: Abriff; Fluticasone propionate/formoterol fumarate; Fluticasone/formoterol; Flutiform; flutiform K-Haler; Flutiformo; Flutiform™ HFA-MDI; Formoterol fumarate/fluticasone propionate; FP/FORM - Vectura; Iffeza; KRP-108Latest Information Update: 04 Feb 2021
Price :
$50
*
At a glance
- Originator SkyePharma PLC
- Developer Kyorin Pharmaceutical; Mundipharma International; Mundipharma Research; SkyePharma PLC; Vectura
- Class Antiallergics; Antiasthmatics; Ethanolamines; Glucocorticoids; Small molecules
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma
- Phase III Chronic obstructive pulmonary disease